N,N-dimethyl Heptylone (hydrochloride)
目录号 : GC47722
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
N,N-dimethyl Heptylone (hydrochloride) is an analytical reference standard categorized as a cathinone. This product is intended for research and forensic applications.
N/A
| Cas No. | N/A | SDF | |
| Canonical SMILES | CN(C)C(CCCCC)C(C1=CC(OCO2)=C2C=C1)=O.Cl | ||
| 分子式 | C16H23NO3.HCl | 分子量 | 313.8 |
| 溶解度 | DMF: 2.5 mg/ml,DMSO: 14 mg/ml,Ethanol: 0.25 mg/ml,PBS (pH 7.2): 3 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1867 mL | 15.9337 mL | 31.8674 mL |
| 5 mM | 0.6373 mL | 3.1867 mL | 6.3735 mL |
| 10 mM | 0.3187 mL | 1.5934 mL | 3.1867 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Experimental and theoretical study on the hydrogen bonding between dopamine hydrochloride and N,N-dimethyl formamide
Spectrochim Acta A Mol Biomol Spectrosc 2015 Jun 15;145:500-504.PMID:25801441DOI:10.1016/j.saa.2015.03.024.
The hydrogen bonding between dopamine hydrochloride (DH) and N,N-dimethyl formamide (DMF) were investigated by UV-visible spectra (UV-Vis), cyclic voltammetry (CV) and density functional theory (DFT). It was found that the position of UV-Vis absorption band and the anodic/cathodic peak potentials of DH were all affected by the concentrations of DH in DMF. It was suggested that hydrogen bonding were formed between DH and DMF, which was confirmed by the DFT results. AIM analyses were performed to elucidate the nature of the hydrogen bonding in the mixtures.
TANAX(T-61): an overview
Pharmacol Res 2000 Apr;41(4):379-83.PMID:10704259DOI:10.1006/phrs.1999.0633.
In this overview the authors describe the use of Tanax (T-61) for euthanasia. Tanax is a solution with three components (embutramide, mebenzonium iodide and tetracaine hydrochloride) used for painless death in pets and laboratory animals. It is also used for malicious intoxication in animals and for suicide attempts in humans. After a description of the modality and outcome of intoxication, the authors report the secondary toxic effects evoked by N, N -dimethyl-formamide, the solvent employed to dissolve the three components of Tanax. Finally, the analytical methods used to identify Tanax components in biological fluids and tissues are described.
Cation-selective electropreconcentration
Lab Chip 2014 Jun 7;14(11):1811-5.PMID:24733115DOI:10.1039/c4lc00024b.
A cation-selective microfluidic sample preconcentration system is described. The cation sample was electropreconcentrated using a reversed-direction electroosmotic flow (EOF) and an anion-permselective filter, where an electric double layer (EDL) overlap condition existed. The anion-permselective filter between microchannels was fabricated by three different methods: 1) extending a positively charged, nanoporous, polymer membrane by photopolymerization of poly(diallyldimethylammonium chloride) (PDADMAC); 2) etching a nanochannel and then coating it with a positively-charged monomer, N-[3-(trimethoxysilyl)propyl]-N'-(4-vinylbenzyl)ethylenediamine hydrochloride (TMSVE); and, 3) etching a nanochannel and then coating it with a positively-charged, pre-formed polymer, polyE-323. The EOF direction in the microchannel was reversed by both TMSVE and polyE-323 coatings. The cation-selective preconcentration was investigated using charged fluorescent dyes and tetramethylrhodamine isothiocyanate (TRITC)-tagged peptides/proteins. The preconcentration in the three different systems was compared with respect to efficiency, dependence on buffer concentration and pH, tolerable flow rate, and sample adsorption. Both TMSVE- and polyE-323-coated nanochannels showed robust preconcentration at high flow rates, whereas the PDADMAC membrane maintained anion-permselectivity at higher buffer concentrations. The TMSVE-coated nanochannels showed a more stable preconcentration process, whereas the polyE-323-coated nanochannels showed a lower peptide sample adsorption and robust efficiency under a wide range of buffer pHs. The system described here can potentially be used for the preconcentration of cationic peptides/proteins on microfluidic devices for subsequent analyses.
A colourimetric sensor for the simultaneous determination of oxidative status and antioxidant activity on the same membrane: N,N-dimethyl-p-phenylene diamine (DMPD) on Nafion
Anal Chim Acta 2015 Mar 20;865:60-70.PMID:25732585DOI:10.1016/j.aca.2015.01.041.
A colourimetric sensor capable of simultaneously measuring oxidative status (OS) in terms of the hazard produced by reactive oxygen species (ROS) and antioxidant activity (AOA) in regard to ROS-scavenging ability of antioxidant compounds was developed. The coloured cationic semi-quinone derivatives, caused by ROS oxidative degradation of N,N-dimethyl-p-phenylene diamine hydrochloride (DMPD) in pH 5.7 acetate-buffered medium, were formed in solution and immobilized on a perfluorosulfonate-based Nafion membrane. ROS, namely hydroxyl (·OH) and superoxide (O2(·-)) radicals, were produced by Fenton/UV and xanthine/xanthine oxidase methods, respectively. The pink-coloured, (+)-charged chromophore (referred to as DMPD-quinone or DMPDQ), resulting from the reaction between DMPD and ROS, could be completely retained on the solid membrane sensor by electrostatic interaction with the anionic sulfonate groups of Nafion. After equilibration, the Nafion membrane surface was homogeneously coloured enabling an absorbance measurement at 514 nm, while the aqueous phase completely lacked colour. Antioxidants, when present, caused an absorbance decrease on the membrane due to their ROS scavenging action, giving rise to less DMPDQ production. The absorbance decrease on the sensor was linearly dependent on antioxidant concentration over a reasonable concentration range, enabling the simultaneous determination of OS and AOA-against ROS. The proposed antioxidant sensing method was tested in synthetic and real antioxidant mixtures, and validated against standard antioxidant capacity assays (i.e. ABTS and CUPRAC) for a variety of polyphenolic and antioxidant compounds. The dynamic linear ranges of antioxidants with the DMPD sensor in protection against hydroxyl and superoxide radicals generally varied within the micromolar to a few tens of micromolar concentration interval over one order-of-magnitude. Choosing three representative compounds in the high (epigallocatechin gallate), medium (quercetin) and low (p-coumaric acid) molar absorptivity range, the detection limits ranged within the concentration intervals of 0.2-0.9 μM, 0.3-0.8 μM, and 4-14 μM, respectively, depending on the radical scavenged.
Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers
J Pharmacokinet Biopharm 1982 Jun;10(3):247-64.PMID:7175698DOI:10.1007/BF01059260.
1,2-O-Isopropylidene-3-O-3'(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride, I, is a substituted sugar with claimed immunomodulatory action. Pharmacokinetic studies in 10 volunteers (bolus i.v., 100 mg) showed respective half-lives for each exponential in the sum of two exponentials that characterized plasma level decay with time of 4.6 +/- 0.4 (SEM) min, t1/2(lambda 1), and 244 +/- 20 min, t1/2(lambda 2)), The total and renal clearances were 277 +/- 20 and 254 +/- 18 (SEM) ml/min, indicative of tubular secretion. Urinary recovery was 93 +/- 2%. The estimated volumes of distribution of the central compartment and overall equilibrated tissues were 14.7 +/- 1.9 and 96 +/- 8 liters, respectively. Sequential daily oral administration of large amounts in capsules (1.2, 2.1, 2.9, 4.1, and 5.0 g) permitted an estimate of 63 +/- 4 (SEM)% bioavailability from urinary recovery of drug, with estimated terminal half-lives of 454 +/- 25 min from minimal data. Orally administered 2.03 g showed a rapid absorption (t1/2 = 10 min) after a lag time of 23 min, and a terminal plasma half-life of 344 min. Plasma protein binding of I was negligible. The erythrocyte/plasma water partition coefficient was close to unity.